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SurvivalAbstract Background: Middle East respiratory syndrome coronavirus (MERS-CoV),
is an emerging virus respiratory infection. It has a high mortality rate and a wide
spectrum of clinical features. This study describes the clinical characteristics and
outcome of MERS infected patients.
Methods: A retrospective study was conducted of all confirmed MERS-CoV infec-
tions from March 2014 to May 2014 at two tertiary care hospitals in Al-Madinah
region (Saudi Arabia). We gathered data about demographic, clinical presentation,
and factors associated with severity and mortality.
Results: A total of 29 cases were identified; 20 males (69%) and nine females
(31%), age 45 ± 12 years. The death rate was higher for men (52%) than for women
(23%). Initial presentation was fever in 22 (75%) cases, cough in 20 (69%) cases,
and shortness of breath in 20 (69%) cases. Associated comorbidities were diabetes
mellitus in nine (31%) patients and chronic kidney disease (CKD) in eight (27%)
patients. Duration of symptoms before hospitalization ranged from 2.9 days to
5 days. Elevated liver enzymes were present in 14 (50%) patients and impaired renal
profile present in eight (27%) patients. We also describe in this study radiological
patterns and factors associated with mortality.ail.com
ail.com
30 N. Sherbini et al.Conclusion: MERS-CoV infection transmission continues to occur as clusters in
healthcare facilities. The frequency of cases and deaths is higher among men than
women and among patients with comorbidities.
 2016 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
In Saudi Arabia, a beta new coronavirus was iso-
lated for the first time at the end of 2012 from a
patient who presented with acute community
acquired pneumonia [1]. He died 11 days later from
progressive severe respiratory failure and acute
renal failure (ARF) and his sputum sample was neg-
ative for respiratory viruses commonly tested. Epi-
demiology of Middle East respiratory syndrome
coronavirus (MERS-CoV) was expanded after
exploring the large hospital outbreak in Al-Hasa,
Saudi Arabia [2]. Subsequently, the virus was desig-
nated as MERS-CoV [3]. The geographic distribution
of the cases has been mainly linked to the Arabian
Peninsula particularly from Saudi Arabia where
most of the cases were reported [4–7]. However,
in some countries in North America, Europe, Africa,
and Asia, the disease has been detected in some
travelers from endemic countries [3,7–13]. The
initial occurrence of MERS-CoV was thought to have
particular predominance for male patients and
those with comorbid diseases. The male-to-
female ratio was between 2.8:1 and 3.3:1 [2,6];
this male predominance might have been related
to the nature of the outbreak. Initial cases were
reported among elderly patients with a median
age of 56 years. MERS-CoV has a very high mortality
rate, and complications arising from infection can
result in severe respiratory and renal failure [2].
Symptoms of MERS-CoV range from mild upper res-
piratory symptoms to rapidly progressive severe
pneumonia requiring intubation, and multiorgan
failure. A significant number of patients may pre-
sent with nonrespiratory symptoms such as head-
ache, myalgia, and gastrointestinal symptoms of
nausea, diarrhea, or vomiting [2,14]. This study
describes the demographic, clinical characteris-
tics, and outcome of MERS-CoV in Al-Madinah
region, Saudi Arabia.
2. Materials and methods
A retrospective chart review study of all confirmed
MERS-CoV cases recorded by two tertiary hospitals
from the Madinah region from March 2014 to May
2014. Institutional Review Board approval wasobtained for our study from authorities of both hos-
pitals. A case was confirmed as having infection if
MERS-CoV real-time polymerase chain reaction
was positive, using the recommended sampling
technique (nasopharyngeal swab and tracheal aspi-
rates or bronchoalveolar lavage in intubated
patients). Extraction of RNA was performed with
Roche MagNa Pure LC (RNA viral isolation Kit). Sam-
ples were pretreated with lysis according to the
manufacturer’s instructions [15]. We obtained data
about demographic characteristics, clinical presen-
tation, laboratory results, diagnosis, incubation
period, smoking history, comorbidities, and history
of contact with camels or MERS-CoV positive
patients in regions within the Madinah area. We
recorded the duration of the patient’s illness,
microbiological test results, and reviewed imaging
and treatments received. We also recorded the fol-
lowing outcomes: duration of mechanical ventila-
tion, intensive care unit (ICU) length of stay, and
survival during hospitalization until the patient is
discharged from hospital.
2.1. Statistical analysis
Data were analyzed using IBM SPSS for Windows,
version 18.0. The frequency of cases of MERS-CoV
infection and percentage of resulting deaths were
calculated. Statistical analyses of demographics,
clinical, and laboratory descriptive data are tabu-
lated. Descriptive statistics such as means and
standard deviation mean (±SD) were used to
describe the age of the patients, laboratory test
results, and duration of illness. Frequencies and
percentages n (%) were used to describe demo-
graphic and MER-COV outcomes. We also did a cor-
relation with the outcome using the t test and
Fisher’s exact test as appropriate with a significant
value at p 6 0.05.3. Results
The total number of cases with confirmed
MERS-CoV infection reported from April 2014 to
May 2014 was 29. The majority of patients (60%)
were men, and the median age was 45 years. The
most common symptoms were fever (75.9%) and
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vomiting and diarrhea (27%). The average duration
of symptoms prior to hospitalization was 5 days
(range, 1–12 days). Demographic and clinical char-
acteristics of patients with confirmed MERS-CoV
are shown in Table 1. Mortality rate among patients
with confirmed MER-CoV was 34%. Mortality from
MERS-CoV was significant (p < 0.05) and associated
with older age, the presence of gastrointestinal
symptoms, longer duration of symptoms prior to
hospitalization (8 ± 2.5 days), diabetes mellitus,
chronic kidney disease (CKD), smokers, and lower
blood pressure, as shown in Table 1.Table 1 Demographic and clinical characteristics of patie
(MERS-CoV) infection according to outcome.
Clinical characteristics Died (n = 10)
No. %
Age (y) Mean ± SD 54.6 ± 13.0
Gender
Male 6 60.0
Female 4 40.0
Symptoms
Fever 9 90.0
Cough 7 70.0
Shortness of breath 8 80.0
Vomiting 7 70.0
Diarrhea 7 70.0
History of chronic diseases
Diabetes mellitus 7 70.0
Chronic kidney disease 8 80.0
Smoking habit
Smoker 10 100.0
Nonsmoker 0 0.0
Duration of disease before hospitalization (d)
Min–Max 4–12
Mean ± SD 8.1 ± 2.5
Vital signs
Pulse
Min–Max 98–154
Mean ± SD 132.5 ± 17.0
Temperature (C)
Min–Max 37.1–39.0
Mean ± SD 38.2 ± 0.5
Systolic blood pressure (mmHg)
Min–Max 90–105
Mean ± SD 98.0 ± 4.8
Diastolic blood pressure (mmHg)
Min–Max 55–65
Mean ± SD 59.0 ± 3.2
SD = standard deviation.
* Denotes significant p value.Most of the patients were coming from Hanakia
11 (38%) and all 11 patients had contact with
camels Table 2. Close contact with confirmed index
MERS-CoV was documented in five patients, all of
whom were healthcare professionals; three staff
nurses and two clinicians.
Most of the patients were mildly hypoxic; oxygen
saturation was 88.9 ± 5.4 at presentation with a
picture of respiratory acidosis (pH 7.3 ± 0.1 and
pCO2 57.1 ± 8.2). The basic liver functions show
elevated alanine transaminase (98.4 ± 105.4 U/L),
aspartate aminotransferase (86.3 ± 93.5 U/L), and
creatinine (225.0 ± 115.3 mmol/L). As shown innts with Middle East respiratory syndrome coronavirus
Survived (n = 19) p
No. %
40.7 ± 8.5 0.002*
14 73.7 0.675
5 26.3
13 68.4 0.367
13 68.4 1.0
12 63.2 0.431
1 5.3 0.001*
1 5.3 0.001*
2 10.5 0.002*
0 0.0 <0.0001*
9 47.4 0.005*
10 52.6
1–6 <0.0001*
3.4 ± 1.3
82–142 <0.0001*
101.0 ± 21.5
37.0–39.1 0.415
38.0 ± 0.6
125–140 <0.0001*
132.6 ± 5.6
70–87 <0.0001*
78.3 ± 6.4
Table 2 Residence within Al-Madinah area of patients
with Middle East respiratory syndrome coronavirus
(MERS-CoV) infection – according to outcome.
Demographic
characteristics
Died
(n = 10)
Survived
(n = 19)
p
No. % No. %
Residence
Al-Madinah 0 0.0 6 31.6 0.045*
Hanakia 6 60.0 5 26.3
Yanbu 1 10.0 3 15.8
Wadi Alfara 0 0.0 3 15.8
Khaibar 1 10.0 2 10.5
Al Mahd 2 20.0 0 0.0
* Denotes significant p value.
32 N. Sherbini et al.Table 3, deaths among patients with MERS-CoV
was significantly associated with worse gas
exchanges pH 7.2 ± 0.1, SPO2 84.8 ± 3.5, lower WBC
3.3 ± 0.9, lower hemoglobin 11.7 ± 1 g/dL, worse
liver enzymes, and kidney function (all p < 0.05).
Other important findings are the sputum culture
results illustrated in Fig. 1, which were collected
during the patient’s initial assessment.Table 3 Laboratory findings of Middle East respiratory syndro
April–May 2013/Al-Madinah.
Laboratory investigations Studied patients
Mean ± SD
Died (n = 10)
Hematologic parameters
WBC 3.3 ± 0.9
Hemoglobin 11.7 ± 1.5
Platelets 253.9 ± 81.5
ABG
pH 7.2 ± 0.1
PCO2 64.1 ± 5.2
PO2 80.3 ± 1.3
SPO2 84.8 ± 3.5
HCO3 22.8 ± 1.3
Chemistry
ALT 203.1 ± 125.9
AST 169.6 ± 123.8
Bilirubin (total) 23.0 ± 3.9
Bilirubin (direct) 15.9 ± 2.2
Creatinine 370.8 ± 60.2
Urea 22.5 ± 1.8
Sodium 146.1 ± 7.9
Potassium 3.9 ± 0.3
Magnesium 0.4 ± 0.2
ABG = arterial blood gases; ALT = alanine transaminase; AST = aspa
* Denotes significant p value.All patients had abnormal initial chest
radiographs. The predominant finding was bilateral
basal consolidations with ground-glass opacities,
nodular or/and reticular pattern, and total diffuse
multilobar involvement. All patients had appropri-
ate supportive management and received a broad
spectrum antibiotic and readjusted based on spu-
tum cultures. Among patients who required ICU,
the mean time of ICU stay ranged from 9 days to
55 days (13.7 ± 4.0 days), and mechanical ventila-
tion support was used in nine (31%) patients.
Mechanical ventilation support and longer stay in
ICU were significantly associated with death
(p < 0.05) (see Table 4).
4. Discussion
Emerging viral respiratory infections are causing a
significant burden on public health and causing sig-
nificant morbidity and mortality. Over the past
decades, many viral infection outbreaks have been
reported including influenza H7N9 such as H1N1,
SARS-CoV, and the most recent MERS-CoV infec-
tion. The World Health Organization reported
1368 laboratory-confirmed cases of human infec-me coronavirus (MERS-CoV) patients according to outcome,
(n = 29) p
Survived (n = 19)
9.0 ± 4.0 <0.0001*
13.2 ± 1.8 0.033*
313.8 ± 78.1 0.064
7.4 ± 0.1 <0.0001*
53.5 ± 7.1 <0.0001*
82.0 ± 1.8 0.012*
91.2 ± 5.0 0.001*
24.5 ± 1.4 0.004*
43.3 ± 8.8 <0.0001*
42.5 ± 6.9 <0.0001*
13.3 ± 2.1 <0.0001*
12.2 ± 1.3 <0.0001*
148.3 ± 29.3 <0.0001*
14.2 ± 2.1 <0.0001*
139.7 ± 3.9 0.033*
3.7 ± 0.3 0.065
0.3 ± 0.1 0.323
rtate aminotransferase.
Fig. 1 Sputum culture results. MRSA = methicillin-resistant Staphylococcus aureus; Staph = Staphylococcus;
Strepto = Streptococcus.
Table 4 Management of Middle East respiratory syndrome coronavirus (MERS-CoV) patients according to outcome,
April–May 2013/Al-Madinah.
Management Died (n = 10) Survived (n = 19) p
No. % No. %
Medication received
Meropenem 8 80.0 12 63.2 0.431
Linezolid 4 40.0 13 68.4 0.236
Levofloxacin 7 70.0 8 42.1 0.245
Piperacillin 4 40.0 11 57.9 0.450
Ribavirin 3 30.0 7 36.8 1.0
Azithromycin 6 60.0 13 68.4 0.698
Interferon 6 60.0 13 68.4 0.698
Steroids 10 100.0 19 100.0 NA
Use of mechanical ventilation 8 80.0 1 5.3 <0.0001*
Duration of ICU stay (d), mean ± SD 18.5 ± 2.3 11.1 ± 1.6 <0.0001*
ICU = intensive care unit; NA = not applicable; SD = standard deviation.
* Denotes significant p value.
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between 2012 and July 2015 [7].
They reported that 65% of cases were male
(n = 1359) and the median age was 50 years
(n = 1365) which is similar to our study. Similar to
a study reported by Assiri et al. [2], our study
showed more cases among older patients, but our
study showed an association of death with older
age.
Since 2012, 26 countries have been affected,
including countries in the Middle East, Africa,
Europe, Asia, and North America as reported from
the World Health Organization. The majority of
cases (75%) have been reported from Saudi
Arabia. In Saudi Arabia, mortality secondary to
MERS-CoV was 35% [16] and in our study it was
37% (Al-Madinah).
Camels have been confirmed as a reservoir for
MERS-CoV, and many hypotheses are behind thiszoonotic (camels) transmission [17,18]. In our
study, only five healthcare employees acquired
infection from documented contact with an
infected patient, but another 24 patients were
coming from areas around Al-Madinah; the largest
number of infected patients was from the Alhenakia
area, where camels are prevalent. The second
important mode of transmission is person-to-
person transmission (travelers returning from the
Middle East and close contacts with MERS-CoV
cases) [19]. This type of transmission was confirmed
by genome sequencing of MERS-CoV [19] and iso-
lates from the Al-Hasa healthcare-associated out-
break [16]. In the UK, MERS-CoV was transmitted
to a family member who visited a patient with con-
firmed infection and another report from France
described patient-to-patient nosocomial transmis-
sion of MERS-CoV. In our study, five (18%) patients
had transmission through close contact.
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study reported diabetes and CKD, which is similar
to those from other observational epidemiological
studies in Saudi Arabia [2,16]. The high mortalities
reported early were probably due to a delay in the
diagnosis and presence of comorbidities [20]. How-
ever, the large number of MERS-CoV cases and CKD
might have been based on the Al-Hasa hospital out-
break, which mainly happened in the dialysis cen-
ter [2]. We may consider the existence of chronic
illnesses such as diabetes, hypertension, and CKD
increasing the risk of acquiring this infection and
categorize them as a high risk group for more com-
plications and worse outcome as was revealed [21]
also in our study.
We and others have found that the severity of
illness associated with MERS-CoV infection ranges
from mild to fulminant [22]. The severity of the
respiratory infections caused by MERS-CoV can pro-
gress to hypoxemic respiratory failure which
requires the use of mechanical ventilation and
death [23]. All of our patients had significant respi-
ratory manifestations requiring admission to the
ICU but 30% only required mechanical ventilation
and died [24]. MERS-CoV is known to infect cell
lines of the intestinal tract [25], but it is not yet
known what proportion of ill patients shed the virus
in their stools, which is why some patients pre-
sented with gastrointestinal symptoms. Identifica-
tion of the full range of clinical presentations is
important so that the mild cases are not missed.
MERS-CoV is detected by reverse transcription
polymerase chain reaction. To date, laboratory
testing for MERS-CoV remains not very accurate;
the sensitivity and negative predictive values are
unknown. Development of rapid and accurate diag-
nostic tests is needed urgently. Results of throat
swabs were occasionally negative and repeat test-
ing for MERS-CoV is recommended. It seems diffi-
cult to conclude that one negative sample is
enough to rule out MERS-CoV disease when a
patient presents with respiratory symptoms and
history of exposure. It is also not clear whether
nasopharyngeal samples might be superior to
throat samples or whether virus is shed more abun-
dantly later in the course of the illness as it is in
SARS. There is evidence that repeat testing and
tests on sputum or bronchoalveolar lavage fluid
are of value in improving diagnostic accuracy.
Microbiological investigations were done rou-
tinely to exclude bacterial copathogens with com-
munity acquired pneumonia (CAP). We had seven
patients with methicillin-resistant Staphylococcus
aureus (MRSA) coinfection, two with Streptococcus
and one with methicillin-sensitive Staphylococcusaureus (MSSA) in our study population. Assiri et al.
[2] stated that none of the 47 samples screened
was positive. Other investigators found that one
patient was coinfected with MSSA and influenza B
and another with Streptococcus pneumonia [23].
There might have been a selection bias because
we were only screening critically ill cases, which in
turn will lead to detection of more severe cases of
MERS-CoV infection; mild cases may not come to
hospital or may not be screened for MERS-CoV
and could lead to false high case-fatality rates.
Clinical symptoms, laboratory investigations, and
imaging findings of MERS-CoV are similar to those
noted in other community-acquired respiratory
tract infections.
Radiological findings in MERS-patients tended to
range from unilateral focal air-space opacities to
multifocal or bilateral lower lobe involvement
was seen with a picture of organizing pneumonia
which was noted in our patients and other reports
[25,26].
On the basis of findings until now, the clinical
features of MERS-CoV infection have similarities
to those seen in patients with SARS-CoV infection.
The initial phase of nonspecific fever, cough, and
shortness of breath are the major symptoms in
those admitted to hospital; other common symp-
toms include chills, rigor, headache, myalgia, and
malaise which may last for several days before pro-
gressing to pneumonia [21,22]. A significant num-
ber of patients had GI symptoms, another
important similarity to SARS. We found patients
with MERS-CoV who had GI manifestation tend to
progress to severe illness and this may be consid-
ered one of the poor prognostic factors. The dis-
ease may progress rapidly to a critical respiratory
failure, requiring mechanical ventilation and lead
to death in the ICU [5]. In our observations, all of
the patients started with symptoms of fever, cough
for 5–7 days.
Our study design has several limitations includ-
ing that it is a retrospective chart review study
with known inherited problems; these include miss-
ing data regarding contact with camels and docu-
mentation of all comorbidities and availability of
follow up data after discharge. Despite these limi-
tations, we have been able to highlight some fea-
tures in the epidemiological, demographic, and
clinical characteristics of patients with MERS-CoV
infection in Al-Madinah regions.
5. Conclusion
The epidemiology and the transmission pattern of
MERS-CoV to date indicate that the majority of
MERS-COV: demographic and clinical data 35cases occur in the healthcare setting. Strengthen-
ing the infection control measures in the health-
care setting is of great importance. Since about
25% of cases are community based, there is a real
need to further prevent the animal-to-human
transmission of MERS-CoV. The frequency of cases
and deaths is higher among men than women and
those around 45 years of age are the most affected
patients. The disease had higher mortality in older
patients with comorbidities. Also, the presence
of gastrointestinal manifestations, high liver
enzymes, and need for mechanical ventilation or
longer stay in ICU are all associated with high
mortality.
There are gaps in our knowledge of the epidemi-
ology, prevalence, clinical characteristics, prog-
nostic factors, and nature of the disease. It is
also important to further delineate the transmis-
sion routes and the presence of any other animal
or intermediate hosts. The influence of geographi-
cal distribution and comorbidities on the incidence
and outcome of MERS-CoV patients should be stud-
ied further.
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